Stocktoria
Novo Nordisk A/S NOVO-B.CO
DK · Nasdaq Copenhagen · XCSE · stock · Healthcare · website
Novo Nordisk A/S financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | kr 309.1B | kr 290.4B | kr 232.3B | kr 177.0B |
| Gross profit | kr 250.3B | kr 245.9B | kr 196.5B | kr 148.5B |
| R&D expense | kr 52.0B | kr 48.1B | kr 32.4B | kr 24.0B |
| SG&A expense | kr 70.3B | kr 67.4B | kr 61.6B | kr 50.7B |
| Operating income | kr 127.7B | kr 128.3B | kr 102.6B | kr 74.8B |
| Interest expense | kr 4.2B | kr 1.6B | kr 542.0M | kr 378.0M |
| Income tax | kr 28.1B | kr 26.2B | kr 21.0B | kr 13.5B |
| Net income | kr 102.4B | kr 101.0B | kr 83.7B | kr 55.5B |
| EPS (diluted) | kr 23.03 | kr 22.63 | kr 18.62 | kr 12.22 |
| Operating cash flow | kr 119.1B | kr 121.0B | kr 108.9B | kr 78.9B |
| Free cash flow | kr 29.0B | kr 69.7B | kr 70.0B | kr 64.1B |
| Cash & equivalents | kr 26.5B | kr 15.7B | kr 14.4B | kr 12.7B |
| Inventory | kr 49.6B | kr 40.8B | kr 31.8B | kr 24.4B |
| Total assets | kr 542.9B | kr 465.6B | kr 314.5B | kr 241.3B |
| Total liabilities | kr 348.9B | kr 322.1B | kr 207.9B | kr 157.8B |
| Shareholders' equity | kr 194.0B | kr 143.5B | kr 106.6B | kr 83.5B |
Growth · year-over-year · Revenue CAGR 20.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +6.4% | +25.0% | +31.3% | — |
| Net income growth | +1.4% | +20.7% | +50.7% | — |
| EPS growth | +1.8% | +21.5% | +52.4% | — |
| Free cash flow growth | -58.4% | -0.5% | +9.2% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · DK · as of 2025-12-31. Figures in DKK; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.